Literature DB >> 15205880

Pre-attentive processing and schizophrenia: animal studies.

Bart A Ellenbroek1.   

Abstract

RATIONALE: Schizophrenia is characterized by a large variety of cognitive symptoms, among which information processing deficits have been extensively studied. So far, these aspects have been found to be remarkably stable and effective treatment is still lacking. Traditionally, information processing is subdivided into pre-attentive (automatic) and attentive processing. Pre-attentive processing refers to the early stages of information processing before conscious attention sets in. Two paradigms most often used to investigate pre-attentive processing are prepulse inhibition and auditory (or P(50)) gating. The advantage of these two paradigms is that they can be used in humans and animals with virtually identical methods.
OBJECTIVE: The present paper aims to highlight the similarities and differences between these two aspects of pre-attentive processing, and to illustrate their usefulness for studying such cognitive deficits in schizophrenia.
METHODS: We evaluated the available animal literature, focusing on both pharmacological and non-pharmacological methods for altering pre-attentive gating.
RESULTS: Even though prepulse inhibition has been investigated much more than P(50) gating, the available literature shows that there are many more differences than similarities between the two paradigms.
CONCLUSIONS: Prepulse inhibition and P(50) gating are mediated through different neuronal mechanisms and therefore both paradigm offer the possibility of developing novel therapeutic targets for the cognitive deficits in schizophrenia. However, such an approach will only be successful when a further integration between clinical and pre-clinical research takes place.

Entities:  

Mesh:

Year:  2003        PMID: 15205880     DOI: 10.1007/s00213-003-1684-7

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  123 in total

Review 1.  Search for schizophrenia susceptibility genes.

Authors:  A E Pulver
Journal:  Biol Psychiatry       Date:  2000-02-01       Impact factor: 13.382

2.  A genome-wide scan for linkage to chromosomal regions in 382 sibling pairs with schizophrenia or schizoaffective disorder.

Authors:  Lynn E DeLisi; Sarah H Shaw; Timothy J Crow; Gail Shields; Angela B Smith; Veronica W Larach; Nigel Wellman; Josephine Loftus; Betsy Nanthakumar; Kamran Razi; John Stewart; Margherita Comazzi; Antonio Vita; Thomas Heffner; Robin Sherrington
Journal:  Am J Psychiatry       Date:  2002-05       Impact factor: 18.112

3.  Prepulse inhibition of the startle response in men with schizophrenia: effects of age of onset of illness, symptoms, and medication.

Authors:  V Kumari; W Soni; V M Mathew; T Sharma
Journal:  Arch Gen Psychiatry       Date:  2000-06

4.  Modulating sensory gating in healthy volunteers: the effects of ketamine and haloperidol.

Authors:  Bob Oranje; Christine C Gispen-de Wied; Marinus Nicholaas Verbaten; René S Kahn
Journal:  Biol Psychiatry       Date:  2002-11-01       Impact factor: 13.382

5.  Sensorimotor gating in boys with Tourette's syndrome and ADHD: preliminary results.

Authors:  F X Castellanos; E J Fine; D Kaysen; W L Marsh; J L Rapoport; M Hallett
Journal:  Biol Psychiatry       Date:  1996-01-01       Impact factor: 13.382

6.  Dopaminergic and noradrenergic modulation of amphetamine-induced changes in auditory gating.

Authors:  K E Stevens; L L Fuller; G M Rose
Journal:  Brain Res       Date:  1991-07-26       Impact factor: 3.252

7.  The DBA/2J strain and prepulse inhibition of startle: a model system to test antipsychotics?

Authors:  B Olivier; C Leahy; T Mullen; R Paylor; V E Groppi; Z Sarnyai; D Brunner
Journal:  Psychopharmacology (Berl)       Date:  2001-07       Impact factor: 4.530

8.  P50 suppression and prepulse inhibition of the startle reflex in humans: a correlational study.

Authors:  B Oranje; B N van Berckel; C Kemner; J M van Ree; R S Kahn; M N Verbaten
Journal:  Biol Psychiatry       Date:  1999-04-01       Impact factor: 13.382

9.  Effects of phencyclidine and phencyclidine biologs on sensorimotor gating in the rat.

Authors:  R S Mansbach; M A Geyer
Journal:  Neuropsychopharmacology       Date:  1989-12       Impact factor: 7.853

10.  Effect of nicotine, lobeline, and mecamylamine on sensory gating in the rat.

Authors:  P Curzon; D J Kim; M W Decker
Journal:  Pharmacol Biochem Behav       Date:  1994-12       Impact factor: 3.533

View more
  9 in total

1.  Mutual independence of 5-HT(2) and α1 noradrenergic receptors in mediating deficits in sensorimotor gating.

Authors:  Sarah K Baisley; Katherine L Fallace; Abha K Rajbhandari; Vaishali P Bakshi
Journal:  Psychopharmacology (Berl)       Date:  2011-09-23       Impact factor: 4.530

Review 2.  Animal models of gene-environment interaction in schizophrenia: A dimensional perspective.

Authors:  Yavuz Ayhan; Ross McFarland; Mikhail V Pletnikov
Journal:  Prog Neurobiol       Date:  2015-10-25       Impact factor: 11.685

3.  Alpha4beta2 nicotinic receptor stimulation contributes to the effects of nicotine in the DBA/2 mouse model of sensory gating.

Authors:  Richard J Radek; Holly M Miner; Natalie A Bratcher; Michael W Decker; Murali Gopalakrishnan; Robert S Bitner
Journal:  Psychopharmacology (Berl)       Date:  2006-05-06       Impact factor: 4.530

Review 4.  Contribution of nonprimate animal models in understanding the etiology of schizophrenia.

Authors:  Noah L Lazar; Richard W J Neufeld; Donald P Cain
Journal:  J Psychiatry Neurosci       Date:  2011-07       Impact factor: 6.186

5.  Are DBA/2 mice associated with schizophrenia-like endophenotypes? A behavioural contrast with C57BL/6 mice.

Authors:  Philipp Singer; Joram Feldon; Benjamin K Yee
Journal:  Psychopharmacology (Berl)       Date:  2009-05-30       Impact factor: 4.530

6.  A novel electrophysiological model of chemotherapy-induced cognitive impairments in mice.

Authors:  M J Gandal; R S Ehrlichman; N D Rudnick; S J Siegel
Journal:  Neuroscience       Date:  2008-09-09       Impact factor: 3.590

Review 7.  Perception measurement in clinical trials of schizophrenia: promising paradigms from CNTRICS.

Authors:  Michael F Green; Pamela D Butler; Yue Chen; Mark A Geyer; Steven Silverstein; Jonathan K Wynn; Jong H Yoon; Vance Zemon
Journal:  Schizophr Bull       Date:  2008-11-20       Impact factor: 9.306

8.  Reduced Prepulse Inhibition as a Biomarker of Schizophrenia.

Authors:  Auxiliadora Mena; Juan C Ruiz-Salas; Andrea Puentes; Inmaculada Dorado; Miguel Ruiz-Veguilla; Luis G De la Casa
Journal:  Front Behav Neurosci       Date:  2016-10-18       Impact factor: 3.558

9.  Modulation of mGlu2 Receptors, but Not PDE10A Inhibition Normalizes Pharmacologically-Induced Deviance in Auditory Evoked Potentials and Oscillations in Conscious Rats.

Authors:  Abdallah Ahnaou; Ria Biermans; Wilhelmus H Drinkenburg
Journal:  PLoS One       Date:  2016-01-25       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.